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ABSTRACT Critically ill patients are frequently treated with empirical antibiotic ther-
apy, including vancomycin and -lactams. Recent evidence suggests an increased
risk of acute kidney injury (AKI) in patients who received a combination of vancomy-
cin and piperacillin-tazobactam (VPT) compared with patients who received vanco-
mycin alone or vancomycin in combination with cefepime (VC) or meropenem (VM),
but most studies were conducted predominately in the non-critically ill population.
A retrospective cohort study that included 2,492 patients was conducted in the in-
tensive care units of a large university hospital with the primary outcome being the
development of any AKI. The rates of any AKI, as deﬁned by the Kidney Disease: Im-
proving Global Outcomes (KDIGO) guidelines, were 39.3% for VPT patients, 24.2% for
VC patients, and 23.5% for VM patients (P 0.0001 for both comparisons). Similarly,
the incidences of stage 2 and stage 3 AKI were also signiﬁcantly higher for VPT pa-
tients than for the patients in the other groups. The rates of stage 2 and stage 3
AKI, respectively, were 15% and 6.6% for VPT patients, 5.8% and 1.8% for VC pa-
tients, and 6.6% and 1.3% for VM patients (P 0.0001 for both comparisons).
In multivariate analysis, the use of vancomycin in combination with piperacillin-
tazobactam was found to be an independent predictor of AKI (odds ratio [OR],
2.161; 95% conﬁdence interval [CI], 1.620 to 2.883). In conclusion, critically ill pa-
tients receiving the combination of VPT had the highest incidence of AKI compared
to critically ill patients receiving either VC or VM.
KEYWORDS acute kidney injury, cefepime, meropenem, piperacillin-tazobactam,
vancomycin
Critically ill patients commonly present with sepsis and with hospital-acquiredinfections often requiring empirical antimicrobial therapy comprised of vancomy-
cin in combination with an antipseudomonal beta-lactam (1, 2). These patients are also
exposed to a multitude of factors, such as hemodynamic shock and nephrotoxins,
which put them at high risk for acute kidney injury (AKI), an outcome associated with
increased morbidity and mortality (3–8).
The current literature shows an association between the combination of vancomy-
cin and piperacillin-tazobactam (VPT) and an increased risk of AKI, although the
mechanism of this association has not been well characterized (9–25). The increased
incidence of AKI with VPT has been observed in comparisons with patients who
received vancomycin alone, vancomycin in combination with cefepime (VC), and
vancomycin in combination with meropenem (VM) in both the adult and pediatric
patient populations (9–25). Available literature supports this association in non-critically
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ill patient populations, but limited studies in the critically ill population have failed to
demonstrate an increased risk of AKI with VPT (14, 24, 26–29).
Other areas of clinical interest and need (which have not fully been previously
assessed) include patients receiving vancomycin in combination with a carbapenem
and patients with baseline renal dysfunction. The objective of the study was to
determine the incidence of AKI in critically ill patients receiving vancomycin in com-
bination with piperacillin-tazobactam, cefepime, or meropenem.
RESULTS
Baseline characteristics. A total of 4,165 patients were identiﬁed as eligible for
evaluation (see Fig. S1 in the supplemental material). The major reasons for exclusion
were receipt of multiple beta-lactams (1,021 patients) and receipt of dialysis prior to
admission (268 patients) or within the ﬁrst 48 h of admission (217 patients). After all
exclusion criteria were applied, 2,492 patients were included in the analysis (1,734 in
the VC arm, 366 in the VPT arm, and 392 in the VM arm).
Table 1 summarizes the baseline characteristics used for the comparisons between
groups. Overall baseline characteristics were fairly well matched. Notable exceptions
included intensive care unit (ICU) location, with VPT use being more common in the
surgical/burn/trauma ICU (SICU) and VC and VM use being more common in the
medical ICU (MICU). More patients in the VPT group had sepsis, systolic blood pressure
of 90 mm Hg, and vasopressor use at baseline than in the VC group. Patients in the
VM group had higher modiﬁed acute physiology and chronic health evaluation II
(APACHE II) scores and a higher Charlson comorbidity index value. Initial vancomycin











Age  SD 56.7 16.8 58.6 17.4 0.072 56.7 16.8 58.1 15.5 0.250
No. (%) of males 189 (51.6) 938 (54.1) 0.392 189 (51.6) 221 (56.4) 0.191
Body weight, kg  SD 87.9 32.5 82.1 87.9 0.002 87.9 32.5 83.6 32.5 0.055
ICU location (%) 0.0001 0.0001
MICU 105 (28.7) 829 (47.8) 105 (28.7) 249 (63.5)
SICU 248 (67.8) 523 (30.2) 248 (67.8) 104 (26.5)
NNICU 13 (3.6) 382 (22.0) 13 (3.6) 39 (9.9)
APACHE II [IQR] 16.02 [12.02–20.01] 16.01 [12.02–20.01] 0.855 16.02 [12.02–20.01] 17.01 [13.02–21.01] 0.043
Charlson score [IQR] 3 [1–5] 3 [1–6] 0.141 3 [1–5] 3 [2–6] 0.005
No. (%) with sepsis 205 (56.0) 688 (39.7) 0.0001 205 (56.0) 213 (54.3) 0.643
No. (%) with mechanical ventilation 189 (51.6) 913 (52.7) 0.724 189 (51.6) 203 (51.8) 0.968
No. (%) with SBP  90 mm Hg 271 (74.0) 1097 (63.3) 0.0001 271 (74.0) 285 (72.7) 0.677
No. (%) with vasopressor use 187 (51.1) 783 (45.2) 0.038 187 (51.1) 218 (55.6) 0.213
No. (%) with nephrotoxin exposure
No. of concomitant nephrotoxins  1 278 (76.0) 1,353 (78.0) 0.387 278 (76.0) 324 (82.7) 0.023
No. of concomitant nephrotoxins  2 152 (41.5) 741 (42.7) 0.672 152 (41.5) 179 (45.7) 0.252
No. of concomitant nephrotoxins  3 63 (17.2) 289 (16.7) 0.799 63 (17.2) 73 (18.6) 0.613
Baseline WBC [IQR] 15.5 [11.2–21.4] 12.8 [8.9–18.3] 0.0001 15.5 [11.2–21.4] 14.3 [9.4–20.3] 0.747
Baseline CrCl [IQR] 65.5 [46.8–94.0] 69.0 [47.0–90.0] 0.902 65.5 [46.8–94.0] 65.0 [46.0–88.0] 0.185
No. (%) with CHF 67 (18.3) 457 (26.4) 0.001 67 (18.3) 101 (25.8) 0.013
No. (%) with COPD 123 (33.6) 623 (35.9) 0.399 123 (33.6) 128 (32.7) 0.780
No. (%) with diabetes 86 (23.5) 341 (19.7) 0.098 86 (23.5) 80 (20.4) 0.304
No. (%) with severe hepatitis 21 (5.7) 73 (4.2) 0.199 21 (5.7) 41 (10.5) 0.018
Initial vancomycin dose (mg) per 24 h [IQR] 2,000 [1,750–3,000] 2,000 [1,500–3,000] 0.087 2,000 [1,750–3,000] 2,000 [1,500–2,500] 0.002
Initial vancomycin trough (g/ml) [IQR] 12.0 [8.1–18.0] 11.6 [7.9–17] 0.034 12.0 [8.1–18.0] 12.0 [8.2–18.1] 0.804
No. of days of antibiotic therapy [IQR] 4.0 [3.0–5.0] 3.0 [3.0–5.0] 0.643 4.0 [3.0–5.0] 3.0 [2.0–5.75] 0.236
aP values are shown for comparisons made separately between VPT and VC and between VPT and VM. Abbreviations: CHF, congestive heart failure; COPD, chronic
obstructive pulmonary disease; CrCl, creatinine clearance; IQR, interquartile range; MICU, medical intensive care unit; NNICU, neurosurgical/neurological intensive care
unit; SBP, systolic blood pressure; SICU, surgical/burn/trauma intensive care unit; VC, vancomycin plus cefepime; VM, vancomycin plus meropenem; VPT, vancomycin
plus piperacillin-tazobactam; WBC, white blood cell count.
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doses were similar between groups, although they were higher in the VPT group than
in the group of patients receiving VM. Patients receiving VPT had a higher initial
vancomycin trough than the VC group, although this difference was clinically negligi-
ble. Antibiotic durations were similar for both comparisons.
Primary outcome. The incidence of AKI was signiﬁcantly higher in patients receiv-
ing the combination of VPT in both comparisons (39.3% for patient receiving VPT,
24.2% for patients receiving VC, and 23.5% for patients receiving VM; P 0.0001 for
both comparisons). Unadjusted odds ratios for any AKI were higher in patients receiv-
ing VPT compared with VC (OR, 2.04; 95% conﬁdence interval [CI], 1.61 to 2.58) and
were higher in patients receiving VPT compared with VM (OR, 2.12; 95% CI, 1.61 to
2.90). Similarly, the incidence of stage 2 and stage 3 AKI was also signiﬁcantly higher for
patients receiving the combination of VPT versus VC and VM (Table 2).
Secondary outcomes. The median time to the occurrence of AKI was signiﬁcantly
longer in patients receiving VPT (3.2 days) than in patients receiving VC (2.6 days),
p 0.03, and VM (2.2 days), p 0.003. Survival analysis of the time to AKI (Fig. 1)
demonstrated a signiﬁcantly increased risk of AKI in the VPT group.
AKI rates based on the four quartiles of baseline creatinine clearance (CrCl) showed
that patients in both quartiles of CrCl values of 90 as well as 90 and 60 ml/min
with VPT receipt were found to have signiﬁcantly increased AKI rates compared with VC
or VM receipt (Fig. 2). A subgroup analysis separating patients into three groups based
on the initial vancomycin trough concentration found an increased incidence of AKI
with progressively higher initial vancomycin troughs in all three combination groups
(Fig. S2). Patients with initial vancomycin trough concentrations of 20 or 15 g/ml
and 20 g/ml had higher rate of AKI than those with concentrations of 15 g/ml
(P 0.0001 in both analyses).
The overall ICU length of stay (LOS) was signiﬁcantly greater in both the VC and VM
groups than in the VPT group (Table 2). Among survivors, those who developed an AKI
during the admission had a longer ICU LOS (145 versus 162 h, P 0.037) and hospital
LOS (13.9 versus 15.3 days, P 0.011) than those who did not develop AKI. Overall
hospital mortality rates were similar in the patients receiving VPT and those receiving
VC; however, they were signiﬁcantly higher in patients receiving VM than in those
receiving VPT (Table 2). In all patients, hospital mortality rates were highest in the MICU
versus the neurosurgical/neurology ICU and the SICU (17.3% versus 14.7% and 12%,
respectively, P 0.0037).
Multivariate analysis. Any-stage AKI occurred in 655 (26.2%) patients. In the
bivariate analysis of patients who did and did not have an AKI, the following factors
were found to be statistically signiﬁcant: modiﬁed APACHE II score, use of one or more













No. (%) with any AKI 144 (39.3) 419 (24.2) 0.0001 144 (39.3) 92 (23.5) 0.0001
No. (%) with stage 2 AKI 55 (15.0) 101 (5.8) 0.0001 55 (15.0) 26 (6.6) 0.0001
No. (%) with stage 3 AKI 24 (6.6) 31 (1.8) 0.0001 24 (6.6) 5 (1.3) 0.0001
No. (%) with RRT 4 (1.1) 21 (1.2) 1.000 4 (1.1) 6 (1.5) 0.754
Day of AKI occurrence 3.2 2.6 2.6 2.5 0.030 3.2 2.6 2.2 2.1 0.003
ICU LOS, h [IQR] 82.5 [46.74–151.0] 94.0 [46.0–214.5] 0.0001 82.5 [46.74–151.0] 94.0 [53.0–210.75] 0.001
ICU LOS – AKI subgroup LOS 93 [51–168] 107 [58–223] 0.013 93 [51–168] 110 [60–220] 0.058
Hospital LOS, days [IQR] 9.0 [6.0–17.0] 9.0 [5.0–16.0] 0.558 9.0 [6.0–17.0] 10.0 [6–17.75] 0.236
No. (%) with hospital mortality 42 (11.5) 265 (15.3) 0.061 42 (11.5) 67 (17.1) 0.028
No. (%) with hospital mortality –no. (%)
in AKI subgroup
25 (17.4) 111 (26.4) 0.018 25 (17.4) 26 (28.3) 0.057
aAbbreviations: AKI, acute kidney injury; ICU, intensive care unit; IQR, interquartile range; LOS, length of stay; OR, odds ratio; RRT, renal replacement therapy; VC,
vancomycin plus cefepime; VM, vancomycin plus meropenem; VPT, vancomycin plus piperacillin-tazobactam.
bP values are shown for comparisons made separately between VPT and VC (OR [95% CI], 2.04 [1.61 to 2.58]) and between VPT and VM (OR, 2.12 [1.61 to 2.90]).
Unadjusted bivariate odds ratio values represent the primary outcome for any AKI. Comparisons were made separately between VPT and VC and between VPT and
VM.
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concomitant nephrotoxic agents, higher initial vancomycin trough concentration, base-
line CrCl value of 60 ml/min, and VPT (see Table S1 in the supplemental material).
In the multivariate regression analysis, the following independent variables were
signiﬁcantly associated with AKI: VPT, baseline CrCl 60 ml/min, vasopressor use, initial
vancomycin trough concentration of 20 mg/dl, and baseline Charlson comorbidity
index (Table 3).
DISCUSSION
Our results demonstrate that critically ill patients receiving the combination of VPT
have an increased risk of AKI compared to those receiving the combination of VC or VM.
Our results suggest that the receipt of VPT is associated with an approximately 15%
increase for any AKI, 10% increase for stage 2 AKI, and 5% increase for stage 3 AKI.
Additionally, in multivariate analysis of the entire cohort, the combination of vanco-
mycin and piperacillin-tazobactam had the highest odds ratio for AKI in this critically ill
population.
The mechanism by which VPT induces AKI has not been well characterized. It has
been thought that vancomycin may cause direct proximal tubular toxicity and/or result
in the formation of obstructive tubular casts (30, 31). The concomitant use of VPT has
been hypothesized to potentiate AKI via acute interstitial nephritis or decreased
secretion of creatinine and vancomycin, but further investigation is warranted to better
elucidate the mechanism (32–34).
Previous studies that identiﬁed the combination of VPT as a risk factor for AKI have
focused predominantly in a non-critically ill patient population (9–25), with only three
studies evaluating this interaction solely in the adult critically ill patient population (14,
FIG 1 Kaplan-Meier survival analysis for acute kidney injury.
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24, 29). Those studies did not identify a difference in nephrotoxicity between popula-
tions of patients receiving combinations of vancomycin and various beta-lactams.
Unfortunately, two of the studies were underpowered for the critically ill patient
population (n 122 and 333), with many competing risk factors for AKI (14, 29). One of
the studies evaluated the brief (72 h) use of combination therapy in critically ill
patients (24). Recent meta-analyses were also unable to adequately assess the inter-
action of VPT in the critically ill patient population due to a lack of adequate data
(26–28).
Our study had several strengths. We believe that our study was able to address
previous study limitations through the use of strict enrollment criteria, large patient
enrollment for analysis, and the evaluation of at least 48 h of combination therapy. The
previous ﬁnding that the use of short (72-h) courses of combination therapy in
critically ill patients does not confer a risk of AKI (29) may also be supported by our
analysis, as our Kaplan-Meier curve data suggest that the observed increase in risk of
AKI occurs at or after 72 h of therapy.
Our study included the largest patient population with baseline renal dysfunction,
FIG 2 Acute kidney injury rates as a function of baseline creatinine clearance.
TABLE 3Multivariate analysis of independent predictors of acute kidney injury in the
combined populationa
Covariate Odds ratio 95% CI
Vancomycin plus piperacillin-tazobactam 2.161 1.620–2.883
Baseline CrCl  60 ml/min 2.220 1.791–2.751
Vasopressor use 1.877 1.512–2.329
Initial vancomycin trough  20 g 1.680 1.281–2.205
Charlson comorbidity index 1.051 1.012–1.091
aVariables included in model: use of piperacillin-tazobactam, cefepime, or meropenem; baseline creatinine
clearance below 60 ml/min; use of one or more vasopressor agent; admission to SICU; Charlson comorbidity
index; initial vancomycin trough value of 20. Backwards logistic regression was used for multivariate
analysis (Hosmer and Lemeshow test value  0.569).
AKI -Lactams and Vancomycin Antimicrobial Agents and Chemotherapy











deﬁned as CrCl 60 ml/min. Although patients with baseline renal dysfunction are
assumed to be at an increased risk of AKI, patients with baseline renal dysfunction have
previously been excluded from analysis. Our analysis suggests that patients with a
baseline CrCl level of 30 ml/min have the highest incidence of AKI with VPT, with an
incidence rate of 55%. This outcome, we believe, is of particular clinical importance due
to the increasing prevalence of chronic kidney disease in the general population and
the risks of chronic kidney disease progressing to end-stage renal disease in critical
illness (35, 36).
Our study also speciﬁcally examined patients who received the combination of VM
as a separate comparison group. Only two previous studies have adequately studied
the combination of VM as a separate analysis, with the other previous analyses
assuming the rates of AKI to be similar to those seen with VC (22, 24). Our results are
consistent with a recent large analysis showing higher rates of AKI with VPT than with
VM (22). We believe that our results provide additional data supporting the use of VM
but recommend caution with respect to the extrapolation of these results to other
carbapenems, such as ertapenem or imipenem/cilastatin, without further investigation.
The ﬁndings of the use of VM resulting in a reduced rate of AKI compared to VPT and
of a similar incidence of AKI compared to VC can be of signiﬁcant clinical importance
when possible alternatives to the combination of VPT are needed.
Our overall results are consistent with previous studies in predominantly non-
critically ill patients, albeit with a higher baseline AKI incidence rate due to the critically
ill patient population being evaluated. The results of our study are also consistent with
previous analyses examining AKI survival (21). Our Kaplan-Meier survival analysis sug-
gests a clear separation in the rates of survival of AKI at day 3 that continues and
increases with each additional day of therapy. Although our median time to AKI was
signiﬁcantly shorter with VC and VM than with VPT, this was likely due to confounding
factors such as other causes of AKI and the sicker patient populations in the VC and VM
groups.
Additionally, our vancomycin trough analysis suggests that the incidence of AKI
continued to be high in patients receiving VPT, despite low initial vancomycin trough
levels. This ﬁnding supports the possibility that the discordant literature on vancomycin
nephrotoxicity may be due to the lack of reporting or control for concomitant anti-
pseudomonal agents (21). The increased rates of AKI with higher initial vancomycin
trough concentrations are also consistent with what has been previously reported (37).
Finally, the similar incidences of AKI in patients receiving VC and VM provide
additional validation that the increased risk associated with VPT is not a result of
confounding variables. In addition, the ﬁnding of increased risk of AKI with VPT in both
comparison groups and the ﬁnding in multivariate analysis of the entire cohort
represent strong validation for this association.
Our study had limitations that should be noted. First, our deﬁnition of AKI did not
include urine output assessment, as we were unable to adequately and consistently
assess this information retrospectively. Previous analysis of AKI with and without urine
output assessment has shown a higher rate of diagnosis of AKI with urine output
assessment (38); thus, our results may represent an underestimation of the risk. While
the data may represent underestimations, the majority of previous analyses of this
interaction have used a deﬁnition without urine output assessment; thus, our results
are consistent with existing VPT literature (9–25).
Second, the possibility of selection bias due to differing indications and the differ-
ences in the critically ill patient populations cannot be ruled out; however, each
subgroup of patient populations evaluated showed no difference in AKI rates based on
ICU location and any ICU location difference in bivariate analysis was accounted for in
the multivariate analysis without a signiﬁcant ﬁnding. In addition, mortality rates were
the highest in the MICU population, indicating a potentially sicker population even with
lower VPT use.
Third, this was a single-center retrospective cohort analysis that included a dispro-
portionate number of patients receiving the combination of VC. This was due to
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cefepime being the primary antipseudomonal beta-lactam agent at our institution. The
decision to include all patients who met inclusion and exclusion criteria was made to
decrease the likelihood of chance ﬁndings in our analysis. Additionally, our institutional
practice utilizes intermittent dosing of antibiotics; thus, our report does not provide any
additional data to support the theory that prolonged or continuous infusions would
result in reduced risk of AKI (39).
Fourth, although we controlled for confounding variables in our study, several
notable confounders need further clariﬁcation. The number of nephrotoxic agents
received by each patient included the cumulative number of agents that met our
deﬁnition; however, we recognize that individual agents are likely to have differing
degrees of nephrotoxicity. We were also unable to collect information on contrast dye
administration; thus, it is not accounted for in our analysis. Additionally, our study
included a large number of patients with sepsis and also encompassed a study period
that included a change in the Surviving Sepsis Campaign Guidelines. This may have
impacted ﬂuid management in the patient being treated with sepsis and may have
resulted in differences in management at differing points in time. However, our
institutional order set for sepsis and ﬂuid management has been previously published
(40) and remained unchanged during this time period, in addition to our use of
dynamic ﬂuid assessment techniques to assess ﬂuid responsiveness.
Finally, we were unable to demonstrate consistent differences in patient-centered
outcomes with respect to ICU LOS and overall morality between comparison groups.
Despite this lack of consistent differences, which can be affected by numerous factors,
including bed availability, the patients in each group with an AKI were consistently
shown to have a higher in-hospital mortality rate, ICU LOS, and overall hospital LOS
than those in the overall group. This association again highlights the importance of
minimizing AKI risk factors for critically ill patients.
Conclusion. Patients experiencing critical illness have multiple risks for AKI which
have previously been shown to have effects on morbidity, mortality, and ICU LOS (3–8).
In this study of critically ill patients, VPT was associated with an increased incidence of
AKI compared separately with VC and with VM. Multivariate analysis of the entire cohort
found the combination of VPT to be the strongest predictor of AKI. This analysis also
found patients receiving VPT with a baseline CrCl rate of 30 ml/min to be at the
highest risk of AKI. In critically ill patients requiring empirical antimicrobial coverage
with vancomycin and an antipseudomonal agent, clinicians should give strong consid-
eration to institutional antimicrobial resistance patterns, likely causative pathogens,
and patient risk of AKI and should consider the use of agents other than the combi-
nation of vancomycin and piperacillin-tazobactam.
MATERIALS AND METHODS
Study settings and design. This was a retrospective cohort study that was conducted at Barnes-
Jewish Hospital, a tertiary referral medical center in St. Louis, MO, with 1,300 adult beds and 155 intensive
care unit (ICU) beds. The institutional review boards of Washington University and St. Louis College of
Pharmacy approved the initiation and design of this study prior to the start of data collection.
Patient population. Patients admitted between 1 August 2014 and 1 August 2017 were evaluated.
Patients were eligible to be included in the study if they were 18 years of age, were admitted to the
medical ICU (MICU), surgical/burn/trauma ICU (SICU), or neurosurgical/neurology ICU (NNICU), and had
received the combination of VPT, VC, or VM for 48 h with each agent initiated within 24 h of initiation
of the other. Additionally, the patient was required to have a baseline serum creatinine (SCr) value during
the evaluated hospitalization prior to or at initiation of antibiotic administration.
Patients were excluded if they had a history of dialysis at any point prior to admission, if dialysis was
initiated within 48 h of antibiotic initiation, if the patient had a history of cystic ﬁbrosis or had been
started on vancomycin plus a beta-lactam agent and the beta-lactam agent had then been changed to
another beta-lactam during the same ICU admission. The ﬁrst hospital admission and the ﬁrst ICU
encounter were used for patients with repeat hospital and ICU admissions. All other admissions were
excluded, and only the ﬁrst administration of combination therapy during the hospitalization was
assessed.
Study outcomes. The primary outcome was the development of any AKI, as determined on the basis
of the Kidney Disease: Improving Global Outcomes (KDIGO) deﬁnition (41), during combination antibiotic
therapy and within 72 h after completion of combination antibiotic therapy. Secondary outcomes
included time to the development of AKI, the need for subsequent dialysis, AKI rates compared with
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vancomycin troughs, AKI rates compared with baseline creatinine clearance (CrCl), ICU and hospital
length of stay (LOS), hospital mortality, and evaluation of overall risk factors for AKI.
Data collection and deﬁnitions. Data abstracted from medical records included baseline demo-
graphics and comorbid conditions, through the Charlson comorbidity index (42). A modiﬁed APACHE II
scoring that excluded the Glasgow coma score (43) was collected along with diagnoses of sepsis and
septic shock, use of vasopressor agents, use of mechanical ventilation, and initial white blood cell count.
Deﬁnitions of AKI were based on the respective SCr cutoffs for KDIGO deﬁnition stage 1 (an increase
in SCr by 1.5 baseline or an increase of 0.3mg/dl from baseline), stage 2 (increase in SCr by 2
baseline), and stage 3 (increase in SCr by 3 baseline), without the inclusion of urine output, as these
data were not readily available for collection.
Initial vancomycin trough levels, if obtained, were evaluated. Subsequent vancomycin doses were
collaboratively adjusted by physicians and pharmacists to target a vancomycin trough similar to those
in national guideline recommendations (44). Our institution utilizes intermittent dosing of vancomycin
and beta-lactam antimicrobial agents. Data corresponding to the use of additional nephrotoxic agents
were collected and categorized, with nephrotoxic medications in this study consisting of aminoglyco-
sides, amphotericin, vasopressors, acyclovir, cidofovir, ganciclovir, foscarnet, chloramphenicol, colistin,
nonsteroidal anti-inﬂammatory drugs, angiotensin-converting enzyme inhibitors/angiotensin receptor
blocking agents, diuretics, and calcineurin inhibitors.
Statistical analysis. For the primary outcome of AKI development deﬁned by the KDIGO deﬁnition,
we estimated that the VPT group would have an increase of at least 10% in AKI compared between
groups, as previously reported (14, 45). We determined a sample size based on an estimated baseline AKI
rate of 25% in our ICUs, from which we estimated we would need at least 328 patients per group to
achieve a statistical power of 80% using an  of 0.05.
The reference group chosen for statistical comparisons was the VPT group. For categorical data, the
Pearson 2 test or Fisher’s exact test was used, as appropriate. For continuous data, the Student’s t test
and Wilcoxon rank sum tests were used, as appropriate. An odds ratio with 95% conﬁdence intervals was
utilized for the primary outcome of any AKI development. For the secondary outcome of time to
development of AKI, comparisons were made with log rank tests for survival analysis from any AKI and
plotted on a Kaplan-Meier curve.
A prespeciﬁed, a priori multivariate analysis was conducted to evaluate risk factors of AKI by
separating the entire patient cohort into two groups based on the development of AKI. Using backwards
logistic regression analysis to control for confounding baseline characteristics, any characteristic corre-
sponding to results of a comparison between groups with a P value of 0.2 and tested for possible
collinearity was included in the model. Statistical analysis was performed by us using SPSS 22 software
(SPSS Inc., Chicago, IL, USA), and all two-sided P values of 0.05 were considered statistically signiﬁcant.
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